# Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy

> **NCT05489458** · — · UNKNOWN · sponsor: **BUSQUETS, JULI** · enrollment: 100 (estimated)

## Conditions studied

- Carcinoma, Pancreatic Ductal

## Interventions

- **PROCEDURE:** Resection
- **PROCEDURE:** No Resection

## Key facts

- **NCT ID:** NCT05489458
- **Lead sponsor:** BUSQUETS, JULI
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2022-10
- **Final completion:** 2023-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489458, "Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05489458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*